HealthQuill Articles by: HealthQuill
Vicebio will receive potential milestone payments of up to $450 million based on development and regulatory achievements.
Drugs Health Pharma

Sanofi to acquire UK’s Vicebio for $1.6b, to pocket vaccine candidates

 HQ Team July 22, 2025: Sanofi SA will acquire UK-based Vicebio Ltd. for $1.6 billion to gain access to vaccine candidates for respiratory

Read More
Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight management and metabolism, and invest $50 billion in the country over five years.
Drugs Health Pharma

AstraZeneca to invest $50 billion in US, to build new drug facility

HQ Team July 22, 2025: Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight

Read More
AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live longer, company data from an end-stage study reveals.
Drugs Health Pharma

AstraZeneca’s therapy for a type of lung cancer helps patients live longer 

HQ Team July 21, 2025: AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live

Read More
Artificial intelligence platforms for psychiatric patients are showing a pattern of racial bias by proposing different treatments for people of colour, a small Cedars-Sinai study finds.
Health Medical Research

AI platforms for psychiatric patients show racial bias: Cedars-Sinai

HQ Team July 17, 2025: Artificial intelligence platforms for psychiatric patients are showing a pattern of racial bias by proposing different treatments for

Read More
AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys, failed to meet its main goal of helping people to live longer.
Drugs Health Pharma

AstraZeneca’s trial drug for AL amyloidosis fails to meet survival goal

HQ Team July 16, 2025: AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys,

Read More
The US Food and Drug Administration has approved a biosimilar product made by India’s Biocon Biologics Ltd., a subsidiary of Biocon Ltd., to treat diabetes mellitus in adults and pediatric patients.
Drugs Health Pharma

US regulator clears Biocon’s diabetic biosimilar product for Novolog

HQ Team July 15, 2025: The US Food and Drug Administration has approved a biosimilar product made by India’s Biocon Biologics Ltd., a

Read More
ViiV Healthcare, majority owned by GSK, has signed a pact with the UN-backed Medicines Patent Pool (MPP) to enable generic access to its HIV treatment in 133 countries.
Drugs Health Pharma

ViiV to grant generic access to its HIV medicine to benefit 133 nations

HQ Team July 15, 2025: ViiV Healthcare, majority owned by GSK, has signed a pact with the UN-backed Medicines Patent Pool (MPP) to

Read More
As the neural code of beauty unfolds, one truth becomes clear: art is not a mere luxury of the soul. It is a language the brain inherently understands.
Drugs Health Opinion

Neuroaesthetics: Art is not a luxury of soul, it is a language of the brain

HQ Team By Aparna S. July 15, 2025: Why does the curve of a statue stir something deep within our soul? Why do

Read More
Zimmer Biomet Holdings, Inc. will acquire Monogram Technologies Inc., an orthopaedic robotics company, for $177 million to expand its robotics portfolio.
Drugs Health Medical

Zimmer Biomet to buy Monogram Technologies for $177 million

HQ Team July 15, 2025: Zimmer Biomet Holdings, Inc. will acquire Monogram Technologies Inc., an orthopaedic robotics company, for $177 million to expand

Read More
Global infant vaccination rates were up marginally last year, but shortfalls in funding, instability, and rising misinformation threaten to block further progress, the UNICEF stated.
Drugs Health Pharma

Funding shortage, conflicts hinder infant vaccination progress: UNICEF

HQ Team July 15, 2025: Global infant vaccination rates were up marginally last year, but shortfalls in funding, instability, and rising misinformation threaten

Read More